| NCL | neuronal ceroid-lipofuscinosis; nucleolin |
|---|---|
| CLF | cardiolipin fluorescent [antibody]; ceroid lipofuscinosis; cholesterol-lecithin flocculation |
| LNP | large neuronal polypeptide |
| SCN1A | sodium channel, neuronal alpha-subunit type 1 |
| INCL | Infantile neuronal ceroid lipofuscinosis |
|---|---|
| JNCL | Juvenile neuronal ceroid lipofuscinosis |
| LINCL | Late infantile neuronal ceroid lipofuscinosis |
| NCL | Neuronal Ceroid Lipofuscinosis |
| CCL | Canine ceroid-lipofuscinosis |
| neuronal ceroid-lipofuscinosis | A heritable lipidosis with cytoplasmic inclusions staining for ceroid and lipofuscin. Clinically the patient has progressive dementia, retinal degeneration, seizures, and myoclonic jerks. It was formerly thought to be related to tay-sachs disease but the biochemical defect is as yet undetermined. Named according to age of onset: jansky-bielschowsky disease, 2-4 years; batten-spielmeyer-vogt disease, 5-11 years; and kufs disease, adult. (12 Dec 1998) |
|---|---|
| ceroid | A naturally occurring lipid pigment with histochemical characteristics similar to lipofuscin. It accumulates in various tissues in certain experimental and pathological conditions. (12 Dec 1998) |
| lipofuscinosis | Abnormal storage of any one of a group of fatty pigments. Ceroid lipofuscinosis, cerebral sphingolipidosis, late juvenile type. Neuronal ceroid lipofuscinosis, a group of diseases characterised by accumulation of abnormal pigments in tissue (previously classified as cerebral sphingolipidoses). Major subtypes include chronic juvenile form (Batten disease), slowly progressive behaviour and visual symptoms, autosomal recessive inheritance; acute, late infantile form (Bielschowsky disease); autosomal recessive inheritance; chronic adult form (Kufs disease), variable inheritance; acute infantile form (Santavuori-Haltia disease), fulminating motor and mental deterioration often associated with myoclonic seizures. Minor forms have also been described. (05 Mar 2000) |
| adrenergic neuronal blocking agent | A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines. (05 Mar 2000) |
| cell adhesion molecules, neuronal | Surface ligands that mediate cell-to-cell adhesion and function in the assembly and interconnection of the vertebrate nervous system. These molecules promote cell adhesion via a homophilic mechanism. These are not to be confused with ncam (neural cell adhesion molecule), now known to be expressed in a variety of tissues and cell types in addition to nervous tissue. (12 Dec 1998) |
| primary neuronal degeneration | <disease> A progressive, neurodegenerative disease characterised by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language. The cause of nerve cell death is unknown but the cells are recognised by the appearance of unusual helical protein filaments in the nerve cells (neurofibrillary tangles) and by degeneration in cortical regions of brain, especially frontal and temporal lobes. Alzheimer's disease is the most common cause of dementia. (22 May 1997) |
| neuronal | <anatomy> Pertaining to a neuron or neurons (= conducting cells of the nervous system). (18 Nov 1997) |
| neuronal differentiation | Acquisition during development of specific biochemical, physiological and morphological properties by nerve cells. (18 Nov 1997) |
| neuronal guidance | <cell biology> General term for mechanisms that ensure correct projections by nerve cells in developing and regenerating nervous systems. Implies accurate navigation by growth cones, the highly motile tips of growing neuronal processes. See: growth cone collapse. (12 Mar 1998) |
| neuronal hyperplasia | Increased numbers of ganglion cells with myenteric plexus hyperplasia and increased acetylcholinesterase activity in nerves of the mucosa and submucosa. Clinically, neuronal hyperplasia mimics Hirschprung's disease. Similar findings are seen in patients with multiple endocrine neoplasia syndrome, type IIB, and in neurofibromatosis. Synonym: hyperganglionosis, neuronal intestinal dysplasia. (05 Mar 2000) |
| neuronal intestinal dysplasia | Increased numbers of ganglion cells with myenteric plexus hyperplasia and increased acetylcholinesterase activity in nerves of the mucosa and submucosa. Clinically, neuronal hyperplasia mimics Hirschprung's disease. Similar findings are seen in patients with multiple endocrine neoplasia syndrome, type IIB, and in neurofibromatosis. Synonym: hyperganglionosis, neuronal intestinal dysplasia. (05 Mar 2000) |
| neuronal plasticity | Ability of nerve cells to change their properties for example by sprouting new processes, making new synapses or altering the strength of existing synapses. See: long-term potentiation. (18 Nov 1997) |
| neuronal polarity | Distribution of specific functions to discrete cellular domains: for example axons and dendrites that have different molecular composition, morphology and ultrastructure and perform different functions. (18 Nov 1997) |
| infantile neuronal degeneration | <neurology, paediatrics> Degenerative disorder of infants with widespread neuronal loss in thalamus, cerebellum, pons, and spinal cord, resembling infantile muscular atrophy. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|